Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency. 1986

M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich

Growth hormone (GH) responses to GRF (1 microgram/kg BW i.v.) were investigated. Comparison between GRF(1-40) and GRF(1-29)NH2 in 11 young adult volunteers gave identical results. One hundred and thirty-one children and adolescents (45 with idiopathic GHD) were tested with GRF (1-29)NH2. The maximal GH levels (max GH) in response to GRF during the 120 min test period were found suitable to characterize the response. In cases without GHD no correlation to age, sex and pubertal development was observed. A maximal GH level of above 10 ng/ml was found to be normal. In 3 out of 86 children without GHD (one with Turner syndrome; two with simple obesity) max GH fell short of 10 ng/ml, while 11 of 45 cases with GHD exceeded this margin. In GHD, max GH was inversely correlated with age. There was no difference in max GH between groups with or without perinatal pathology as a presumed cause of GHD. GH levels to GRF were positively correlated with maximal GH level during sleep in GHD, but not correlated with responses seen to insulin or arginine. The value of GRF testing for the confirmation of GHD is discussed in the light of other GH stimulatory tests and basal somatomedin C measurements. It is suggested that the combination of testing with GRF and the determination of a basal SmC level offers a safe and convenient way to diagnose GHD in clinically suspected cases, though in some cases further diagnostic tests may be needed.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D007223 Infant A child between 1 and 23 months of age. Infants
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010901 Pituitary Function Tests Examinations that evaluate functions of the pituitary gland. Pituitary Gland Function Tests,Function Test, Pituitary,Function Tests, Pituitary,Pituitary Function Test,Test, Pituitary Function,Tests, Pituitary Function
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females

Related Publications

M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
May 1992, Journal of medicinal chemistry,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
September 1985, Acta endocrinologica,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
January 1988, Acta pharmaceutica Suecica,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
January 1986, Acta endocrinologica. Supplementum,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
May 1987, Deutsche medizinische Wochenschrift (1946),
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
March 1993, Acta paediatrica (Oslo, Norway : 1992). Supplement,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
January 1987, Reproduction, nutrition, developpement,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
March 1984, Chemical & pharmaceutical bulletin,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
March 1993, Acta paediatrica (Oslo, Norway : 1992). Supplement,
M B Ranke, and M Gruhler, and R Rosskamp, and G Brügmann, and A Attanasio, and W F Blum, and J R Bierich
August 1983, Biochemical and biophysical research communications,
Copied contents to your clipboard!